Matthew Appenzeller, MD
Ophthalmology · Omaha, NENPI 1235340522
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 11 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Alcon accounts for 68.4% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2022 at $390 and has fallen 62.1% since, to $148 in 2025.
Across 11 payments — averaging $105.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$793
- Novartis$229
- Rxsight Inc$120
- Genentech, Inc.$18
What the payments were for
- Food & beverage$1,159100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 7 | $793 |
| Novartis | 2 | $229 |
| Rxsight Inc | 1 | $120 |
| Genentech, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,159 in reported general payments places this provider in the 60th percentile of 105 ophthalmology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 21 | $21,495 |
| Latanoprost | 447 | $3,709 |
| CombiganBrimonidine Tartrate/Timolol | 14 | $3,411 |
| Fluorometholone | 49 | $3,293 |
| Travoprost | 20 | $2,706 |
| Prednisolone Acetate | 59 | $2,322 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 81 | $1,183 |
| Brimonidine Tartrate | 32 | $900 |
| Timolol Maleate | 166 | $823 |
| Ketorolac Tromethamine | 41 | $455 |
| MoxifloxacinMoxifloxacin Hcl | 17 | $453 |
| Doxycycline Hyclate | 12 | $83 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Omaha
- Brandon BaartmanOmaha$226K
- Ronald KruegerOmaha$224K
- Lorraine ProvencherOmaha$220K
- Lance KuglerOmaha$41K
- Rao ChunduryOmaha$14K
- Shane HavensOmaha$6K
- Brandon MenkeOmaha$6K
- Sao LiuOmaha$5K
- Michael HalstedOmaha$4K
- Thomas HejkalOmaha$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.